Pharma & Biotech
Verona Pharma looks forward to phase III ensifentrine trials
ImmuPharma targets regulatory approval as follow-up study confirms “outstanding” safety profile of Lupuzor
ImmuPharma continues to build data package for flagship lupus treatment
Only registered members can use this feature.
© Proactive Investors 2019.
Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.